Breaking News

TSRL Receives $2.2M NIH Grant

Aims to advance the development of a weekly microneedle patch for the treatment of overactive bladder (OAB).

Author Image

By: Charlie Sternberg

Associate Editor

TSRL Inc.,  a preclinical contract research organization (CRO) specializing in formulation development, bioanalysis, exploratory toxicology, and pharmacokinetic strategies to guide human dosing schedules, has received a new $2.2 million grant award from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH) under Award Number R44DK143799, to advance the development of a weekly microneedle patch for the treatment of overactive bladder (OAB). T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters